Gilead: Will New HIV Drugs Overshadow Hep C Worries?

At a current $77.49, Gilead Sciences’ ( GILD ) share price has plunged 37% since hitting a record high $123.27 last summer amid growing anxiety among investors about a slowdown in the company’s blockbuster hepatitis C drugs Sovaldi and Harvoni. But what about HIV medications? The franchise is a massive part of Gilead's business. And according to Citigroup’s Robyn Karnauskas , an analysis of weekly prescription data shows that new therapies account for more than one-third of the prescriptions written for Gilead’s HIV medications.